Cell Therapy Medical Safety &
Pharmacovigilance
Cell therapy products carry a distinct safety profile. Cytokine release syndrome, ICANS, prolonged cytopenias, and on-target off-tumor
Toxicities demand dedicated medical safety oversight that understands the biology, not just the regulatory forms.
DES Pharma serves as a trusted extension of your team across clinical and commercial safety operations.
Because Cell Therapy Patient Safety Requires Focused OversightCell Therapy Medical Safety
and Pharmacovigilance
CAR-T-associated CRS can escalate from grade 1 to grade 4 within hours. ICANS requires
neurologist-graded assessment. Long-term insertional oncogenesis risk demands 15-year follow-up programs. These are not analogous to conventional biologic adverse events, and they require medical safety professionals who understand the biology behind the risk. When in-house capacity is limited, DES Pharma provides the leadership, scale, and clinical judgment needed to move cell therapy programs forward with confidence.
Phase 1/2:
Proactive signal detection, CRS and ICANS risk characterization, risk mitigation strategy, and safety communication for early-stage cell therapy programs, with specific attention to cell therapy-specific toxicities and CBER/OTAT IND safety requirements.
Learn more ▾
- Cell therapy-specific medical safety strategies (CRS grading, ICANS monitoring, cytopenia management)
- Regulatory safety strategies aligned to CBER/OTAT IND requirements
- Safety portions of TPPs, study protocols, Investigator Brochures, and dose justifications
- Proactive safety monitoring and communication with clinical sites
- Independent Data Safety Monitoring Board (DSMB) / DMC support
- Signal detection, risk mitigation strategies, and implementation
- CRS and ICANS grading scale selection and protocol integration (ASTCT, CTCAE)
- Aggregate safety reports and PSURs
- REMS strategy assessment for products with significant CRS or neurotoxicity risk
- Risk characterization and mitigation for autologous and allogeneic programs
- Marketing authorization application safety submissions
- QPPV designation and PV system setup
- Epidemiology support for indication-specific safety contextualization
Phase 3/Post-Authorization
Comprehensive Phase 3 and post-approval safety oversight for cell therapy programs: de-risking development, satisfying CBER/OTAT regulatory expectations, and protecting patients across the product lifecycle, including long-term follow-up obligations.
Learn more ▾
- Continuous risk characterization, mitigation strategy, and implementation through Phase 3 and commercialization
- Independent DSMBs for pivotal cell therapy trials
- Risk Management Plans (RMPs) and Company Core Data Sheets (CCDSs)
- Prescribing label safety section authorship (USPI, SmPC) with cell therapy-specific toxicity language
- Long-term follow-up (LTFU) protocol design and oversight per FDA LTFU guidance — 15-year observation, integration site analysis, secondary malignancy monitoring
- REMS program design, implementation, and ongoing management where required by FDA
- Post-market safety study design and execution oversight
- BLA safety section authorship (CTD Module 2.7.4)
Pharmacovigilance
Global, inspection-ready pharmacovigilance systems for cell therapy products, combining compliant case management, blinded oversight, strong governance, and rapid regulatory response to de-risk development and support lifecycle safety obligations.
Learn more ▾
- Pharmacovigilance Agreements (PVAs) with clinical partners, CDMOs, and apheresis centers
- ICSR processing, reporting, and oversight with cell therapy-specific AE coding (CRS, ICANS, secondary malignancies)
- PV quality systems and training programs
- KPIs and metrics for cell therapy PV operations
- Blinding processes for case processing and reporting oversight in randomized trials
- Pharmacovigilance System Master File (PSMF) development and maintenance
- Expanded PV capacity for large-scale Phase 3 and post-approval programs
- Expedited reporting compliance (7-day and 15-day SUSARs) to CBER/OTAT
Our medical safety and pharmacovigilance teams combine strategic insight with hands-on execution to deliver safety solutions that support confident clinical decision-making, regulatory success,
and sustainable cell therapy program growth. We see the patient behind every batch record,
and that drives everything we build.
Get Started
Advance Your Cell Therapy
Program with Confidence
Start building reliable, inspection-ready medical safety and
pharmacovigilance systems for your cell therapy program today.